

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 09/594,983  
Filed June 15, 2000  
Page 4

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-97. (Canceled)

98. (Previously Presented) A monoclonal antibody designated PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) or a fragment of antibody PA14 which binds to an epitope of chemokine receptor 5 (CCR5) present on the surface of a cell expressing CCR5, which epitope comprises a combination of amino acid residues in (a) the N-terminus of CCR5, and (b) the second extracellular loop of CCR5.

99. (Previously Presented) A hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) which produces a monoclonal antibody designated PA14.

100. (Currently Amended) A monoclonal antibody or a fragment of such antibody, wherein the antibody or the fragment of such antibody binds to the same epitope as monoclonal antibody PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB12610) ~~of claim 99.~~

101. (Currently Amended) A monoclonal antibody or a fragment of such antibody consisting of complementarity determining regions (CDRs) wherein said CDRs are derived

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 09/594,983  
Filed June 15, 2000  
Page 5

from the hybridoma cell line designated PA14 (ATCC  
Accession No. HB12610) ~~of claim 99.~~

102. (Currently Amended) The monoclonal antibody ~~or fragment  
of such antibody~~ according to claim 100, wherein the  
antibody ~~or fragment of such antibody~~ is a humanized  
antibody.
103. (Previously Presented) The monoclonal antibody according  
to claim 102, wherein the antibody comprises a framework  
from a human immunoglobulin molecule.
104. (Previously Presented) The monoclonal antibody according  
to claim 103, wherein the human immunoglobulin molecule  
is selected from the group consisting of IgG1, IgG2,  
IgG3, IgG4, IgA and IgM.
- 105-117. (Canceled)
118. (Currently Amended) The monoclonal antibody ~~or fragment  
of such antibody~~ according to claim 101, wherein the  
antibody is a humanized antibody.
119. (Currently Amended) The monoclonal antibody ~~or fragment  
of such antibody~~ according to claim 118 ~~117~~, wherein the  
antibody comprises a framework from a human IgG2  
immunoglobulin molecule.
120. (Currently Amended) The monoclonal antibody ~~or fragment  
of such antibody~~ according to claim 118 ~~117~~, wherein the  
antibody comprises a framework from a human IgG4

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 09/594,983  
Filed June 15, 2000  
Page 6

immunoglobulin molecule.

121. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 104 ~~102~~, wherein the  
antibody comprises a framework from a human IgG2  
immunoglobulin molecule.
122. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 104 ~~102~~, wherein the  
antibody comprises a framework from a human IgG4  
immunoglobulin molecule.
123. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 100, wherein the  
antibody is a chimeric antibody.
124. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 101, wherein the  
antibody is a chimeric antibody.
125. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 123, wherein the  
antibody comprises a framework from a human IgG2  
immunoglobulin molecule.
126. (Currently Amended) The monoclonal antibody ~~or fragment~~  
~~of such antibody~~ according to claim 123, wherein the  
antibody comprises a framework from a human IgG4  
immunoglobulin molecule.
127. (Currently Amended) The monoclonal antibody ~~or fragment~~

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 09/594,983  
Filed June 15, 2000  
Page 7

~~of such antibody~~ according to claim 124, wherein the antibody comprises a framework from a human IgG2 immunoglobulin molecule.

128. (Currently Amended) The monoclonal antibody ~~or fragment of such antibody~~ according to claim 124, wherein the antibody comprises a framework from a human IgG4 immunoglobulin molecule.

129. (Currently Amended) The monoclonal antibody fragment according to claim 100, wherein the antibody fragment is a ~~monovalent~~ fragment of ~~an~~ a humanized antibody.

130. (Currently Amended) The monoclonal antibody fragment according to claim 101, wherein the antibody fragment is a ~~monovalent~~ fragment of ~~an~~ a humanized antibody.

131. (Currently Amended) The ~~monovalent~~ monoclonal antibody fragment according to claim 129, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.

132. (Currently Amended) The ~~monovalent~~ monoclonal antibody fragment according to claim 129, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.

133. (Currently Amended) The ~~monovalent~~ monoclonal antibody fragment according to claim 130, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG2 immunoglobulin molecule.

Applicants: William C. Olson and Paul J. Maddon  
Serial No.: 09/594,983  
Filed June 15, 2000  
Page 8

134. (Currently Amended) The ~~monovalent~~ monoclonal antibody fragment according to claim 130, wherein the humanized antibody fragment comprises a fragment of a framework from a human IgG4 immunoglobulin molecule.